-
-
-
-
-
-
-
Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio'
-
-
-
-
-
-
-
JPMorgan just refreshed its Analysts Focus List and added these 4 stocks
-
-
-
-
-
-
-
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
-
-
-
-
-
-
1,185,382 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

